Dopavision Announces Topline Results in Clinical Trial of Targeted Photobiomodulation Approach for Progressive Myopia

Dopavision announced topline findings from its MyopiaX-1 proof-of-concept clinical trial (NCT04967287). MyopiaX delivers targeted photobiomodulation to the eye with the aim of managing the progression of myopia among children.

The 6-month outcomes of the randomized, controlled trial demonstrate the safety and tolerability of MyopiaX, according to Dopavision. Conducted across six European countries, the trial randomized 124 myopic children in a 2:1 fashion to MyopiaX or a control group. Over 6 months, treatment with MyopiaX shows signals of clinical effect on the rate of myopia progression.

MyopiaX was safe and tolerable over the 6-month trial period, with no ocular safety events reported.

MyopiaX is a first-in-class, targeted intervention that non-invasively stimulates specific cells in the eye to regulate innate signaling pathways and slow the rate of myopia progression. MyopiaX offers an intuitive and child-friendly digital platform that seamlessly integrates myopia treatment into daily routines leveraging consumer electronics. This approach facilitates ease of use and broad accessibility worldwide, aiming to address the growing global public health challenge of myopia, with projections indicating nearly half of the world’s population will be myopic by 2050.

The ongoing MyopiaX-1 clinical trial is scheduled to complete in September 2024. Dopavision is engaged in discussions with regulatory authorities to outline the potential pathways for MyopiaX’s development and approval.